A patient is on the table. The shipment missed its flight.

An operations leader at a Phase 2 autologous cell therapy company described a real incident to us. A patient was already in the operating room for a tumor resection when the company discovered that the cryogenic container had not made its connecting flight out of Los Angeles. The team had to locate a pre-conditioned shipper at a nearby warehouse coordinating an emergency alternative while the patient was on the table.

That incident is not an outlier. It is a preview. The gap between logistics complexity and team capacity is not static, and three structural forces are converging to make it more acute.

The biologics boom

Biopharmaceuticals are growing at roughly 9% annually and are projected to account for 57% of global pharmaceutical sales by 2030, up from under 10% in the early 2000s. Unlike traditional small-molecule drugs, biologics are temperature-sensitive, time-sensitive, and often patient-specific. A shipping failure is not a reorder. It is a patient whose surgery is delayed, a clinical trial that misses an enrollment window, or a sample that has to be recollected.

The cell and gene therapy inflection

Cell and gene therapies are among the most logistically demanding products ever shipped. Autologous therapies, where a specific patient's cells are collected, modified, and returned to that same patient, have zero tolerance for delay. There is no backup product. There is no safety stock. A failed shipment is not a logistics failure; it is a patient safety event. Radiopharmaceuticals add a different constraint: short half-lives that turn every transit hour into a potential lost dose. In addition to flawless logistics execution, regulatory compliance, temperature control, and Class 7 safety also play a role.

The rural and at-home expansion

The geography of healthcare delivery is shifting at the same time. Specialty medications, diagnostic kits, and clinical trial materials are increasingly shipped to patients at home and to clinic sites in rural markets that lack the logistics infrastructure of urban academic medical centers. The surface area of last-mile complexity is expanding precisely when the products being shipped demand more precision.

The arithmetic doesn't work

Put the three forces together: more shipments, of more sensitive products, to more difficult destinations, under more regulatory scrutiny. And because today's tools leave every exception to a human, exception management scales linearly with headcount: 20% more shipments demand roughly 20% more coordinators, in a market where experienced ones are scarce and expensive. The arithmetic doesn't work. Teams cannot hire their way out of a complexity curve that compounds annually. Something in the operating model has to change.

What's coming in this series

Part 2: the benchmark metric that separates dashboards from operating systems. 

Part 3: why your control tower can see the problem but cannot fix it. 

Part 4: the alert fatigue trap. 

Part 5: AI-native versus AI-bolted-on, and why architecture decides everything. 

Part 6: compliance and the SOP that executes itself. 

Part 7: the right question to ask any vendor, and three steps to take today.

Next week: if on-time delivery rate cannot tell you whether your operation is keeping up, what metric can? Read the full white paper at zoomlogi.com/white-paper/not-another-control-tower.